Price (delayed)
$1.3
Market cap
$40.35M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.49
Enterprise value
$40.77M
DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic
There are no recent dividends present for DRRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.